Editorial: Defining corticosteroid use in clinical trials
- PMID: 39310944
- DOI: 10.1111/apt.18211
Editorial: Defining corticosteroid use in clinical trials
References
REFERENCES
-
- Dorrington AM, Selinger CP, Parkes GC, Smith M, Pollok RC, Raine T. The historical role and contemporary use of corticosteroids in inflammatory bowel disease. J Crohns Colitis. 2020;14(9):1316–1329.
-
- Ma C, Hussein IM, Al‐Abbar YJ, Panaccione R, Fedorak RN, Parker CE, et al. Heterogeneity in definitions of efficacy and safety endpoints for clinical trials of Crohn's disease: a systematic review. Clin Gastroenterol Hepatol. 2018;16:1407–1419.
-
- George J, Singh S, Dulai PS, Ma C, Nguyen T, Feagan BG, et al. Corticosteroid‐free remission vs overall remission in clinical trials of moderate‐severe ulcerative colitis and Crohn's disease. Inflamm Bowel Dis. 2020;26(4):515–523.
-
- Schreiber S, Cross RK, Panaccione R, D'Haens G, Bossuyt P, Dotan I, et al. Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid‐free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease. Aliment Pharmacol Ther. 2024;60:897–906.
-
- Loftus EV Jr, Panés J, Lacerda AP, Peyrin‐Biroulet L, D'Haens G, Panaccione R, et al. Upadacitinib induction and maintenance therapy for Crohn's disease. N Engl J Med. 2023;388(21):1966–1980.
Publication types
LinkOut - more resources
Full Text Sources